Testing a new pill to prevent breast cancer recurrence

Plain-English translation of NCT05834764 on ClinicalTrials.gov ↗ · Source last updated April 2023 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a medication called to see if it can help prevent HER2-positive breast cancer from coming back after standard treatment. You would take this medication by mouth every day for one year. The researchers believe this treatment may offer additional protection beyond what current standard care provides.

Previous research showed that extending anti-HER2 therapy after initial treatment helped some patients, but those studies used older treatment combinations. Doctors want to test whether this medication works better when added after the newer, more effective standard treatments that are used today.

Do you qualify?

You likely qualify if…

you have been diagnosed with HER2-positive breast cancer at stage II, III, or early locally advanced stage
you have already completed standard treatment with trastuzumab combined with pertuzumab or T-DM1
you are between 18 and 75 years old
you have a good overall health status (able to carry out normal activities with minimal symptoms)
you have lymph node involvement or did not achieve a complete response to chemotherapy before surgery

You likely don't qualify if…

you have metastatic (stage IV) breast cancer or inflammatory breast cancer
you have a history of another cancer (except non-melanoma skin cancer or cervical cancer in situ)
you have significant heart problems, uncontrolled high blood pressure, or a history of heart attack
you have a known allergy to this medication
you have a history of gastrointestinal disease with chronic diarrhea

What participation looks like

You would take a daily pill ( 400mg) by mouth for one year while being monitored by the research team. The trial will track how well you tolerate the medication and whether it helps prevent your cancer from returning. You will have regular check-ups and follow-up visits to monitor your health and watch for any side effects during this one-year treatment period.

AI-generated summary from trial data · Jun 18, 2026 · Not medical advice

Trial locations(1 site)

China

JiangSu Province Hospital/ The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu